Vertex completes concurrent offer of shares and convertible notes

Vertex Pharmaceuticals has reported the completion of its public offerings of 6.9 million shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5 million aggregate principal amount of 4.75% convertible senior subordinated notes due 2013, including $37.5 million aggregate principal amount of notes purchased by the underwriters pursuant to their over-allotment option.